How Modulation of Apoptotic Pathways Can Fill Important Unmet Needs in LA SCCHN
Host: Jonathan D. Schoenfeld, MD, MPhil, MPH
\n\n Guest: Robert L. Ferris, MD, PhD
\n\n\n \n
The treatment of LA SCCHN has remained largely unchanged for >2 decades and the standard of care, concurrent chemoradiotherapy (CRT) with high-dose cisplatin, is associated with substantial toxicity and limited efficacy. Inhibitors of apoptosis proteins (IAPs) may well change that dynamic. Join Drs. Jonathan Schoenfeld and Robert Ferris as they focus attention on this unmet need and critically evaluate how therapeutic modulation of the apoptotic pathway may improve patient outcomes.